DRMA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DRMA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Dermata Therapeutics's average basic shares outstanding for the quarter that ended in Sep. 2024 was 1.56 Mil.
The historical data trend for Dermata Therapeutics's Shares Outstanding (Basic Average) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermata Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Shares Outstanding (Basic Average) | 0.04 | 0.04 | 0.02 | 0.05 | 0.20 |
Dermata Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Shares Outstanding (Basic Average) | Get a 7-Day Free Trial | 0.21 | 0.26 | 0.44 | 0.68 | 1.56 |
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
Dermata Therapeutics (NAS:DRMA) Shares Outstanding (Basic Average) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Be Aware
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Thank you for viewing the detailed overview of Dermata Therapeutics's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.
Brittany Bradrick | director | C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130 |
Gerald T Proehl | 10 percent owner, officer: Pres., CEO and Chairman | |
Van Hoose Kyri K. | officer: Chief Financial Officer | C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Mary Fisher | director | C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532 |
David F Hale | director | 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024 |
Steven J Mento | director | C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804 |
Wendell Wierenga | director | C/O CIPHERGEN BIOSYSTEMS INC, 6611 DUMBARTON CIRCLE, FREMONT CA 94555 |
Kathleen D. Scott | director | C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127 |
Thomas Insley | officer: Chief Financial Officer | SKINMEDICA, INC., 5909 SEA LION PLACE, SUITE H, CARLSBAD CA 92010 |
Bedoya-toro Munera Maria E | officer: Senior VP | 10590 WEST OCEAN AIR DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Andrew Seth Sandler | director | 1301 2ND AVE, SEATTLE WA 98101 |
Christopher J. Nardo | officer: Senior VP, Development | C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130 |
Proehl Investment Ventures Llc | 10 percent owner | C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #332, SAN DIEGO CA 92130 |
From GuruFocus
By ACCESSWIRE • 09-06-2024
By ACCESSWIRE • 01-05-2024
By ACCESSWIRE ACCESSWIRE • 05-24-2023
By ACCESSWIRE • 08-08-2024
By ACCESSWIRE • 02-12-2024
By ACCESSWIRE • 08-31-2023
By GuruFocus News • 11-15-2024
By ACCESSWIRE • 08-11-2023
By ACCESSWIRE ACCESSWIRE • 06-14-2023
By ACCESSWIRE ACCESSWIRE • 06-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.